GlassScriptPhysician profile
Jeannot Kekedjian
NPI 1306672365
$1,362.85
in general payments reported to CMS, 2019-2025
9 companies · $955 in 2025
The $955 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $408 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $297.59 | 2025 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $259.24 | 2024 | Reblozyl |
| Celgene Corporation | $213.09 | 2025 | Reblozyl, Breyanzi |
| Jazz Pharmaceuticals INC. | $148.84 | 2024 | |
| Astellas Pharma US INC | $139.79 | 2025 | Xospata |
| Pharmaessentia USA Corporation | $132.33 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2025 | Calquence |
| Sobi, INC | $31.85 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.13 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeannot Kekedjian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.